...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Technical Innovations & Patient Support in Radiation Oncology >A pilot study of patient reported outcomes evaluating treatment related symptoms and quality of life for men receiving high dose rate brachytherapy combined with hypo-fractionated radiotherapy or hypo-fractionated radiotherapy alone for the treatment of localised prostate cancer
【24h】

A pilot study of patient reported outcomes evaluating treatment related symptoms and quality of life for men receiving high dose rate brachytherapy combined with hypo-fractionated radiotherapy or hypo-fractionated radiotherapy alone for the treatment of localised prostate cancer

机译：一项对患者的试验性研究报告了结果，该结果评估了接受高剂量率近距离放射疗法结合单纯分割放疗或单纯单纯分割放疗的男性治疗局部前列腺癌的治疗相关症状和生活质量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patient Reported Outcome Measures (PROMS) are useful metrics in evidence-based clinical care and translational research. Recording treatment-related symptoms and Quality of Life (QoL) can provide information in counselling patients to aid decision-making. This prospective study tested the feasibility of radiographer-led collection of multiple validated PROMS from Prostate Cancer (PCa) patients comparing High Dose Rate Brachytherapy combined with hypo-fractionated external beam radiotherapy (hEBRT) and hEBRT alone. From June to August 2017, 20 men with localised PCa (T1-T3aN0M0) consented to participate in the study. Ten patients received combination treatment (37.5 Gray/15 fractions followed by a 15 Gray implant), and ten patients received monotherapy (60 Gray/20 fractions). PROMS were collected at four time-points (1) at baseline, (2) final fraction of hEBRT, (3) 8?weeks after commencing radiotherapy and (4) 12?weeks after commencing radiotherapy. The PROMS used were EPIC-26, IPSS, IIEFF-5 and SF-12. The difference between the two groups were tested using Mann-Whitney U test and Wilcoxon Signed-Rank Test. All participants completed all PROMS (100% response-rate). The Monotherapy group reported a higher incidence of bowel symptoms compared to the combination group and at Week 12, EPIC-26 bowel summary score demonstrated a statistically significant difference (p?=?0.005). The prevalence of erectile dysfunction increased within both groups. Maintenance of QoL was reported throughout treatment. This small study demonstrated feasibility of radiographer-led PROMS collection by 100% completion rate. Streamlining of these tools into integrated technology applications and real time PROMS measurement has the ability to benefit patients and guide clinicians in adapting therapies based on individual need.
机译：患者报告的结果衡量标准（PROMS）是基于证据的临床护理和转化研究的有用指标。记录与治疗有关的症状和生活质量（QoL）可为咨询患者提供信息以帮助决策。这项前瞻性研究比较了高剂量率近距离放射疗法与超分形外束放射疗法（hEBRT）和单独的hEBRT的比较，以放射线师指导从前列腺癌（PCa）患者中收集多个经过验证的PROMS的可行性。从2017年6月至2017年8月，有20位具有局部PCa（T1-T3aN0M0）的男性同意参加该研究。十名患者接受了联合治疗（37.5 Gray / 15分数，之后是15格雷植入物），十名患者接受了单一疗法（60 Gray / 20分数）。在四个时间点收集PROMS：（1）基线;（2）hEBRT的最终分数;（3）开始放疗后8周;和（4）开始放疗后12周。使用的PROMS是EPIC-26，IPSS，IIEFF-5和SF-12。使用Mann-Whitney U检验和Wilcoxon Signed-Rank检验检验两组之间的差异。所有参与者均完成了所有PROMS（100％答复率）。与联合治疗组相比，单药治疗组的肠症状发生率更高，在第12周时，EPIC-26肠摘要评分显示出统计学上的显着性差异（p≥0.005）。两组中勃起功能障碍的患病率均升高。在整个治疗过程中均报告维持QoL。这项小型研究以100％的完成率证明了由放射线师主导的PROMS收集的可行性。将这些工具简化为集成技术应用程序和实时PROMS测量功能，可以使患者受益，并指导临床医生根据个人需要调整治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号